Mental Health

In 2010, approximately forty two million antidepressant items were dispensed in England. By 2024/25, that figure reached 92.6 million. The population grew 9.5% in the same period.

Sertraline prescriptions increased 685% between 2008 and 2022, making it the most commonly prescribed antidepressant in England.

The SMILES trial, published in BMC Medicine in 2017, randomised patients with moderate to severe depression to either dietary intervention or social support. The dietary group achieved 32.3% remission versus 8% in the control group. The number needed to treat was 4.1, with a large effect size.

Cryan and Dinan identified the gut-brain axis as a bidirectional communication system in their 2012 Nature Reviews Neuroscience paper. Kelly and colleagues demonstrated in 2016 that faecal microbiota transplant from depressed patients to germ-free rats induced depressive behaviour.

Baglioni et al.'s 2011 meta-analysis in the Journal of Affective Disorders synthesised twenty-one prospective longitudinal studies with a combined sample of over 30,000 participants. Individuals with insomnia or habitual short sleep (under six hours) had a relative risk of 2.53 for developing new-onset depression compared with normal sleepers, after adjusting for confounders. The relationship was bidirectional but the prospective design confirmed that sleep disturbance preceded depression onset in the majority of cases.

This is because sleep deprivation disrupts the prefrontal-amygdala circuit, reducing top-down emotional regulation and amplifying amygdala reactivity to negative stimuli by approximately 60 per cent (Yoo et al. 2007, Current Biology). Chronic sleep restriction also impairs hippocampal consolidation of positive memories while preserving negative memories, creating a cognitive bias towards threat and loss. REM sleep is essential for overnight emotional processing, and its curtailment produces measurable increases in next-day anxiety and irritability.

One in three British adults reports sleeping fewer than six hours per night. The Health Survey for England does not include sleep duration as a standard mental health risk factor. NICE depression guideline NG222 mentions insomnia as a symptom of depression but does not address sleep improvement as a primary prevention strategy. Freeman et al.'s 2017 Oxford RCT showed that treating insomnia with digital CBT-I reduced paranoia, hallucinations and depression by 20 to 30 per cent in 3,755 university students, demonstrating that sleep is a causal rather than merely correlational factor.

The vagus nerve, the longest cranial nerve in the body, forms the primary communication highway between the gut and the brain. Approximately eighty per cent of its fibres are afferent (gut to brain) and only twenty per cent are efferent (brain to gut). Bravo et al.'s 2011 study in PNAS demonstrated this directionality by showing that a specific Lactobacillus strain (L. rhamnosus JB-1) reduced anxiety and depression-related behaviour in mice and altered GABA receptor expression in the brain, but only when the vagus nerve was intact. Vagotomised mice (with the vagus nerve severed) showed no behavioural or neurochemical response to the same bacteria.

This anatomical fact inverts the common assumption that mental health is primarily a brain disorder. The gut microbiome produces over ninety per cent of the body's serotonin (via enterochromaffin cells), substantial quantities of GABA, dopamine and short-chain fatty acids that cross the blood-brain barrier. The composition of the gut microbiome, which is determined primarily by diet, directly modulates the neurochemistry of the brain through the vagus nerve. This means that dietary changes alter gut microbial composition, which alters neurotransmitter production, which alters mood and cognition. The gut is not merely digestive: it is a neuroendocrine organ.

Howren et al.'s 2009 meta-analysis in Psychosomatic Medicine pooled 136 studies and found that depressed individuals had significantly elevated levels of C-reactive protein (CRP, effect size d = 0.15, corresponding to approximately forty-six per cent higher levels), interleukin-6 (IL-6, d = 0.25) and interleukin-1 (IL-1, d = 0.35) compared with non-depressed controls. Miller and Raison's 2016 review in Nature Reviews Immunology provided the conceptual framework: depression may be an evolutionary adaptation to sickness behaviour, triggered by inflammatory cytokines that signal infection or tissue damage.

The inflammatory hypothesis of depression explains several puzzles: why depression frequently co-occurs with inflammatory diseases (rheumatoid arthritis, IBD, cardiovascular disease); why anti-cytokine therapies (infliximab) reduce depressive symptoms in treatment-resistant patients; and why SSRIs, which have anti-inflammatory properties independent of their serotonergic effects, may work partly through immune modulation. If depression is substantially driven by systemic inflammation, then interventions targeting inflammation, particularly dietary changes that reduce metabolic endotoxemia and inflammatory food intake, become first-line treatments rather than adjuncts.

Singh et al.'s 2023 network meta-analysis in the British Journal of Sports Medicine pooled 218 randomised controlled trials with 14,170 participants across multiple exercise modalities and depression severity levels. Walking and jogging achieved a standardised mean difference of −1.14, dance −0.96, yoga −0.82 and strength training −0.69. All modalities with sufficient trial data exceeded the pooled SSRI benchmark. The dose-response relationship was robust: higher intensity produced larger effects, with diminishing returns beyond 150 minutes per week.

This is because exercise simultaneously modulates at least four neurobiological pathways implicated in depression: it increases hippocampal brain-derived neurotrophic factor (BDNF), reduces systemic IL-6 and TNF-alpha, normalises HPA axis cortisol output and increases tryptophan availability for serotonin synthesis. No single pharmaceutical targets all four pathways simultaneously. Antidepressants primarily modulate serotonin and, in the case of SNRIs, noradrenaline reuptake.

NHS antidepressant prescriptions reached 85.6 million items in 2023-24, a figure that has more than doubled since 2010. NHS exercise referral schemes received approximately £7 million in designated funding in the same year. The ratio of pharmaceutical to exercise investment is roughly fifty-five to one, despite the 218-trial evidence base showing comparable or superior effect sizes for structured physical activity.

A meta-analysis of twenty-one studies by Lane et al. found that high ultra-processed food consumption was associated with a fifty-three per cent higher odds of depression compared to low consumption, with consistent findings across continents and age groups.

UPFs reduce dietary tryptophan bioavailability, disrupt gut microbiome diversity and promote neuroinflammation through emulsifiers and additives. Each of these mechanisms has independent evidence linking it to depressive symptomatology.

Depression is the leading cause of disability worldwide. The convergence of nutritional epidemiology, gut-brain axis research and microbiome science now makes the dietary contribution to the global mental health crisis difficult to dispute.

The SMILES trial randomised 67 adults with moderate to severe depression. The dietary intervention group received 7 sessions of nutritional counselling emphasising whole foods, fish, vegetables, legumes and nuts.

After 12 weeks, 32% of the dietary group achieved full remission compared to 8% in the control group. No medication changes were made during the trial.

Lurie et al.'s 2015 population-based study in the Journal of Clinical Psychiatry analysed medical records of over one million patients in the UK (THIN database) and found a dose-dependent association between antibiotic exposure and subsequent depression and anxiety. A single antibiotic course increased depression risk by twenty-four per cent (adjusted OR 1.24). Two to five courses increased risk by forty per cent. Five or more courses increased risk by fifty-two per cent. The association held for all antibiotic classes, with fluoroquinolones showing the strongest link.

The mechanism is consistent with gut-brain axis disruption: antibiotics deplete gut microbiome diversity (Dethlefsen 2011 showed that a single course of ciprofloxacin reduced gut species richness by approximately thirty per cent), reducing microbial serotonin and GABA production, increasing intestinal permeability and promoting inflammatory cytokine release. The dose-response relationship, more courses producing greater risk, suggests cumulative microbiome damage that is not fully reversed between exposures. UK GPs prescribe approximately thirty-five million antibiotic courses per year. Depression is the leading cause of disability in the UK. The two trends may not be coincidental.

Suicide is the leading cause of death for men under 50 in the United Kingdom. In 2024, there were 7,147 registered suicides. The male rate was 17.1 per 100,000 and 2023 recorded the highest rate since 1999.

Generalised anxiety disorder in 16 to 24 year olds increased from 1.1% to 7.6% between 2000 and 2023, according to the Adult Psychiatric Morbidity Survey.

A 2023 JAMA Network Open study of over 70,000 participants found that those in the highest quintile of ultra-processed food consumption had a hazard ratio of 1.49 for depression compared to the lowest quintile.

The conversation focuses on mental health services and access to therapy. It rarely examines what people are eating, drinking and absorbing every day.

Liao et al.'s 2019 meta-analysis in Translational Psychiatry pooled twenty-six randomised controlled trials (n = 2,160) of omega-3 polyunsaturated fatty acid supplementation for depression. EPA-predominant formulations (those with an EPA-to-DHA ratio above 1.5) produced a Hedges' g effect size of 0.56, classified as a medium effect. DHA-predominant formulations showed no significant benefit. The EPA-specific effect was consistent across subgroup analyses stratified by baseline depression severity and concurrent antidepressant use.

This is because eicosapentaenoic acid (EPA) competes with arachidonic acid for cyclooxygenase and lipoxygenase enzyme binding, shifting the balance of downstream eicosanoids from pro-inflammatory prostaglandin E2 and leukotriene B4 towards anti-inflammatory resolvins and protectins. Neuroinflammation is now recognised as a driver of at least a subset of depression, particularly treatment-resistant depression. The omega-6-to-omega-3 ratio in modern Western diets is estimated at 15:1 to 20:1, compared with an ancestral ratio of approximately 1:1 to 2:1.

The British National Formulary does not list omega-3 fatty acids as a treatment option for depression. NICE guideline NG222 does not mention omega-3 supplementation. A medium effect size from 26 RCTs and 2,160 participants represents a larger evidence base than most non-pharmacological interventions currently recommended by NICE for depression. EPA supplements cost approximately £8 to £12 per month in the United Kingdom, compared with average monthly SSRI prescribing costs of £3 to £15 depending on the agent.

Davies and Read (2019, Addictive Behaviors) conducted a systematic review of 24 studies involving over 5,000 patients and found that 56% of people who attempt to discontinue antidepressants experience withdrawal symptoms. Nearly half (46%) of those who experienced withdrawal rated the severity as "severe." The mean duration of withdrawal symptoms was far longer than suggested by clinical guidelines, with some patients reporting symptoms lasting months or years.

This is because SSRIs cause neuroadaptive changes in serotonin receptor density and sensitivity. The brain downregulates serotonin receptors in response to artificially elevated serotonin levels, creating a state of physical dependence. Upon withdrawal, the brain must upregulate receptor density back to baseline, a process that can take weeks to months. Horowitz and Taylor (2019, The Lancet Psychiatry) demonstrated that the relationship between dose reduction and serotonin transporter occupancy is hyperbolic, meaning that reductions from low doses produce disproportionately large neurochemical effects.

NICE guidelines in the UK were updated in 2022 to acknowledge that withdrawal can be "severe" and "prolonged," reversing decades of clinical guidance that described symptoms as "mild" and "self-limiting." By 2022, over 8 million adults in England alone were prescribed antidepressants. The average duration of use has risen from weeks (as originally intended for acute episodes) to years, with many patients unable to stop due to withdrawal effects that are clinically indistinguishable from relapse.

Hunter et al.'s 2019 study in Frontiers in Psychology measured salivary cortisol in thirty-six participants who spent twenty minutes or more in a natural setting (park, garden, urban green space). Cortisol levels dropped by 21.3 per cent per hour of nature exposure. The largest cortisol reduction occurred in the first twenty to thirty minutes, with diminishing returns thereafter. Bratman et al.'s 2015 PNAS study additionally demonstrated that a ninety-minute walk in a natural setting reduced self-reported rumination and neural activity in the subgenual prefrontal cortex, a brain region associated with depression.

The average UK adult spends over ninety per cent of their time indoors. Children in the UK spend less time outdoors than prison inmates in some studies. Attention restoration theory (Kaplan 1995) proposes that natural environments engage "involuntary attention" (effortless fascination), allowing the directed-attention system used in work and screens to recover. The cortisol reduction from twenty minutes of nature exposure is comparable to the effect of a session of mindfulness meditation, without requiring training, practice or an app subscription. Nature exposure is a free, evidence-based intervention with no side effects that is essentially absent from NHS mental health care pathways.